Patients with a higher expression level of NFYB had a worse prognosis for kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) but a better prognosis for BLCA, cervical squamous cell carcinoma, and endocervical adenocarcinoma (CESC), brain lower-grade glioma (LGG), LIHC, sarcoma (SARC), and skin cutaneous melanoma (SKCM). Here, NFYB is linked to cutaneous melanoma.